Skip to main content

Table 2 Univariate associations of baseline variables with successful TNFi discontinuation

From: Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment

Predictor OR 95% CI P
anti-TNF monoclonal antibodya 2.26 1.53–3.34 < 0.0001
Concomitant DMARD 1.21 0.51–2.85 0.670
Female sex 1.07 0.72–1.60 0.735
Younger age (≤60 yrs.) 1.17 0.80–1.70 0.417
Shorter disease duration (≤10 yrs.) 2.00 1.34–2.98 0.001
RF negative 1.14 0.75–1.74 0.530
ACPA negative 1.06 0.70–1.62 0.775
Non-erosive 1.62 1.08–2.44 0.020
Normal weight (BMI 18.5–25) 1.35 0.92–1.98 0.128
First TNFi 1.23 0.71–2.13 0.461
DAS28 deep remission (DAS28 ≤ 1.98) 1.21 0.83–1.77 0.314
Low or moderate MBDA (≤44) 2.32 1.32–4.05 0.003
  1. aReference category is receptor antagonist
  2. TNFi tumor necrosis factor-alpha inhibitors, csDMARD conventional synthetic disease modifying anti-rheumatic drug, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide, BMI body mass index, DAS28 disease activity score in 28 joints, MBDA multi-biomarker disease activity